Keith Clinch

Keith Clinch

Auto-generated profile, based on publicly available information

Keith Clinch

The Ferrier Research Institute, Victoria University of Wellington, Wellington, New Zealand

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
VSVipender Singh
Vipender Singh
GEGary B. Evans
Gary B. Evans
DLDirk H. Lenz
Dirk H. Lenz
JMJennifer M. Mason
Jennifer M. Mason
KCKeith Clinch
Keith Clinch
VSVern L. Schramm
Vern L. Schramm
Escherichia coli 5'-methylthioadenosine/S-adenosyl-homocysteine nucleosidase (MTAN) hydrolyzes its substrates to form adenine and 5-methylthioribose (MTR) or S-ribosylhomocysteine (SRH). 5'-Methylthioadenosine (MTA) is a by-product of polyamine synthesis and SRH is a precursor to the biosynthesis of one or more quorum sensing autoinducer molecules. MTAN is therefore involved in quorum sensing, recycling MTA from the polyamine pathway via adenine phosphoribosyltransferase and recycling MTR to methionine. Hydrolysis of MTA by E. coli MTAN involves a highly dissociative transition state with ribooxacarbenium ion character. Iminoribitol mimics of MTA at the transition state of MTAN were synthesized and tested as inhibitors. 5'-Methylthio-Immucillin-A (MT-ImmA) is a slow-onset tight-binding inhibitor giving a dissociation constant (K(i)(*)) of 77 pm. Substitution of the methylthio group with a p-Cl-phenylthio group gives a more powerful inhibitor with a dissociation constant of 2 pm. DADMe-Immucillins are better inhibitors of E. coli MTAN, since they are more closely related to the highly dissociative nature of the transition state. MT-DADMe-Immucillin-A binds with a K(i)(*) value of 2 pm. Replacing the 5'-methyl group with other hydrophobic groups gave 17 transition state analogue inhibitors with dissociation constants from 10(-12) to 10(-14) m. The most powerful inhibitor was 5'-p-Cl-phenylthio-DADMe-Immucillin-A (pClPhT-DADMe-ImmA) with a K(i)(*) value of 47 fm (47 x 10(-15) m). These are among the most powerful non-covalent inhibitors reported for any enzyme, binding 9-91 million times tighter than the MTA and SAH substrates, respectively. The inhibitory potential of these transition state analogue inhibitors supports a transition state structure closely resembling a fully dissociated ribooxacarbenium ion. Powerful inhibitors of MTAN are candidates to disrupt key bacterial pathways including methylation, polyamine synthesis, methionine salvage, and quorum sensing. The accompanying article reports crystal structures of MTAN with these analogues.

8 March 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MHMeng-Chiao Ho
Meng-Chiao Ho
WSWuxian Shi
Wuxian Shi
ARAgnes Rinaldo-Matthis
Agnes Rinaldo-Matthis
PTPeter C. Tyler
Peter C. Tyler
GEGary B. Evans
Gary B. Evans
VSVern L. Schramm
Vern L. Schramm
Inhibition of human purine nucleoside phosphorylase (PNP) stops growth of activated T-cells and the formation of 6-oxypurine bases, making it a target for leukemia, autoimmune disorders, and gout. Four generations of ribocation transition-state mimics bound to PNP are structurally characterized. Immucillin-H ( , first-generation) contains an iminoribitol cation with four asymmetric carbons. DADMe-Immucillin-H ( , second-generation), uses a methylene-bridged dihydroxypyrrolidine cation with two asymmetric centers. DATMe-Immucillin-H ( , third-generation) contains an open-chain amino alcohol cation with two asymmetric carbons. SerMe-ImmH ( , fourth-generation) uses achiral dihydroxyaminoalcohol seramide as the ribocation mimic. Crystal structures of PNPs establish features of tight binding to be; 1) ion-pair formation between bound phosphate (or its mimic) and inhibitor cation, 2) leaving-group interactions to N1, O6, and N7 of 9-deazahypoxanthine, 3) interaction between phosphate and inhibitor hydroxyl groups, and 4) His257 interacting with the 5′-hydroxyl group. The first generation analogue is an imperfect fit to the catalytic site with a long ion pair distance between the iminoribitol and bound phosphate and weaker interactions to the leaving group. Increasing the ribocation to leaving-group distance in the second- to fourth-generation analogues provides powerful binding interactions and a facile synthetic route to powerful inhibitors. Despite chemical diversity in the four generations of transition-state analogues, the catalytic site geometry is almost the same for all analogues. Multiple solutions in transition-state analogue design are available to convert the energy of catalytic rate enhancement to binding energy in human PNP.

1 March 2005 in Journal of Bacteriology
Verified
Journal Article
Open access
PDF file
JRJung-Hyun Rho
Jung-Hyun Rho
DWDamian P. Wright
Damian P. Wright
DCDavid L. Christie
David L. Christie
KCKeith Clinch
Keith Clinch
RFRichard H. Furneaux
Richard H. Furneaux
ARAnthony M. Roberton
Anthony M. Roberton
A novel enzyme which may be important in mucin degradation has been discovered in the mucin-utilizing anaerobe Prevotella strain RS2. This enzyme cleaves terminal 2-acetamido-2-deoxy-β- d -glucopyranoside 6-sulfate (6-SO 3 -GlcNAc) residues from sulfomucin and from the model substrate 4-nitrophenyl 2-acetamido-2-deoxy-β- d -glucopyranoside 6-sodium sulfate. The existence of this mucin-desulfating glycosidase (sulfoglycosidase) suggests an alternative mechanism by which this bacterium may desulfate sulfomucins, by glycosidic removal of a sulfated sugar from mucin oligosaccharide chains. Previously, mucin desulfation was thought to take place by the action of a specific desulfating enzyme, which then allowed glycosidases to remove desulfated sugar. Sulfate removal from sulfomucins is thought to be a rate-limiting step in mucin degradation by bacteria in the regions of the digestive tract with a significant bacterial flora. The sulfoglycosidase was induced by growth of the Prevotella strain on mucin and was purified 284-fold from periplasmic extracts. Tryptic digestion and sequencing of peptides from the 100-kDa protein enabled the sulfoglycosidase gene to be cloned and sequenced. Active recombinant enzyme was made in an Escherichia coli expression system. The sulfoglycosidase shows sequence similarity to hexosaminidases. The only other enzyme that has been shown to remove 6-SO 3 -GlcNAc from glycoside substrates is the human lysosomal enzyme β- N -acetylhexosaminidase A, point mutations in which cause the inheritable, lysosomal storage disorder Tay-Sachs disease. The human enzyme removes GlcNAc from glycoside substrates also, in contrast to the Prevotella enzyme, which acts on a nonsulfated substrate at a rate that is only 1% of the rate observed with a sulfated substrate.

26 January 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KCKeith Clinch
Keith Clinch
GEGary B. Evans
Gary B. Evans
RFRichard F. G. Fröhlich
Richard F. G. Fröhlich
RFRichard H. Furneaux
Richard H. Furneaux
PKPeter M. Kelly
Peter M. Kelly
AWAnthony D. Woolhouse
Anthony D. Woolhouse

1 June 2012 in Chemistry & Biology
Verified
Journal Article
Closed access
KHKeith Z. Hazleton
Keith Z. Hazleton
MHMeng-Chiao Ho
Meng-Chiao Ho
MCMaria B. Cassera
Maria B. Cassera
KCKeith Clinch
Keith Clinch
DCDouglas R. Crump
Douglas R. Crump
VSVern L. Schramm
Vern L. Schramm

26 January 2006 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
KCKeith Clinch
Keith Clinch
GEGary B. Evans
Gary B. Evans
GFGeorge W. J. Fleet
George W. J. Fleet
RFRichard H. Furneaux
Richard H. Furneaux
SJStephen W. Johnson
Stephen W. Johnson
PTPeter C. Tyler
Peter C. Tyler
(1R)-1-(9-Deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-L-ribitol [(+)-5] and (3S,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol [(−)-6] are the L-enantiomers of immucillin-H (D-ImmH) and DADMe-immucillin-H (D-DADMe–ImmH), respectively, these D-isomers being high affinity transition state analogue inhibitors of purine nucleoside phosphorylases (PNPases) developed as potential pharmaceuticals against diseases involving irregular activation of T-cells. The C-nucleoside hydrochloride D-ImmH [(−)-5)·HCl], now “Fodosine™” is in phase II clinical trials as an anti-T-cell leukaemia agent, while D-DADMe–ImmH is a second generation inhibitor with extreme binding to the target enzyme and has entered the clinic for phase I testing as an anti-psoriasis drug. Since the enantiomers of some pharmaceuticals have revealed surprising biological activities, the L-nucleoside analogues (+)-5·HCl and (−)-6, respectively, of D-ImmH and D-DADMe–ImmH, were prepared and their PNPase binding properties were studied. For the synthesis of compound (−)-6 suitable enzyme-based routes to the enantiomerically pure starting material (3S,4S)-4-(hydroxymethyl)pyrrolidin-3-ol [(−)-16] and its enantiomer were developed. The L-enantiomers (+)-5·HCl and (−)-6 bind to the PNPases approximately 5- to 600-times less well than do the D-compounds, but nevertheless remain powerful inhibitors with nanomolar dissociation constants.